Lexeo Therapeutics Q3 2026 Results: Net Loss of $38.3M, Loss Widens
Lexeo Therapeutics reported total assets of $243.9 million as of September 30, 2026, a decrease from $268.7 million at year-end 2025. The company maintains a strong liquidity position with $90.2 million in cash and cash equivalents and $104.6 million in current U.S. Treasury securities to fund its ongoing clinical development of LX2006 and LX2020.
- Key figure
- Net loss $38.3M